Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: equality impact assessment - guidance development

Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: final appraisal determination information

Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: final appraisal determination document

Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: final appraisal determination document (PDF 426 KB)

Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: evaluation report information

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): appraisal consultation

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): appraisal consultation document information

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): evaluation report information

GIST- imatinib (adjuvant) (rev TA196): equality impact assessment - scoping

GIST- imatinib (adjuvant) (rev TA196): final scope

GIST- imatinib (adjuvant) (rev TA196): final matrix

GIST- imatinib (adjuvant) (rev TA196): response to consultee and commentator comments on the draft scope and provisional matrix

GIST - imatinib (adjuvant) (rev TA196): draft scope (post-referral)

GIST - imatinib (adjuvant) (rev TA196): provisional matrix (post-referral)